 |
|
Penn researchers find treatment for MS also reduces vision loss in MS patients
April 17, 2007First MS study to include a test of visual function
According to a study that appears in the April 17 issue of Neurology, researchers at the University of Pennsylvania School of Medicine have found that natalizumab (TYSABRI®) - a drug that slows disability and reduces relapse rates in patients with multiple sclerosis (MS) - also reduces vision loss in patients with relapsing MS. Vision loss is one of the most common and disabling symptoms of MS.
"Not only does natalizumab prevent the worsening of vision loss in people with relapsing MS, but it is also associated with significant reductions in the likelihood of sustained vision loss due to inflammatory demyelination of nerve fibers that connect to the eye, a common cause of visual loss in MS," says Laura J. Balcer, MD, MSCE, Associate Professor of Neurology and Ophthalmology at Penn, and lead author of the paper.
The researchers analyzed data from two randomized, double-blind, placebo-controlled, parallel group, phase 3 clinical trials involving 2,138 men and women with relapsing MS from clinical centers in Europe, North America, Australia, and New Zealand. More than half of the participants received natalizumab every four weeks for two years, while the remaining participants received placebo. Visits were conducted every 12 weeks and visual function testing was performed at each study visit. Low-contrast letter acuity was measured using low-contrast letter charts (eye charts with gray letters on a white background).
Researchers found vision loss - a worsening of vision defined as a two-line (10-letter) reduction in letter chart scores - was reduced by as much as 47% among people taking natalizumab, compared to those taking placebo.
"Not only do the findings of the study add to our understanding of the effects of natalizumab, but the results provide strong validation for a simple, sensitive, cost-effective, and clinically meaningful measure of visual function in MS," advises Dr. Nicholas LaRocca, Associate Vice President, Health Care Delivery and Policy Research at the National MS Society.
The researchers caution that, as with any therapy, the benefits of natalizumab must be considered in the context of potential risks or complications. In the case of natalizumab, three confirmed cases of progressive multifocal leukoencephalopathy (PML) - a rare, often lethal brain disease - have been reported.
Despite the fact that vision loss is a common and important cause of disability in MS, the natalizumab clinical trials were the first to include a test of visual function. These trials showed that low-contrast letter acuity eye chart testing is an effective measure for assessing visual outcomes, and may be useful in future clinical trials.
University of Pennsylvania School of Medicine
The researchers analyzed data from two randomized, double-blind, placebo-controlled, parallel group, phase 3 clinical trials involving 2,138 men and women with relapsing MS from clinical centers in Europe, North America, Australia, and New Zealand. More than half of the participants received natalizumab every four weeks for two years, while the remaining participants received placebo. Visits were conducted every 12 weeks and visual function testing was performed at each study visit. Low-contrast letter acuity was measured using low-contrast letter charts (eye charts with gray letters on a white background).
Researchers found vision loss - a worsening of vision defined as a two-line (10-letter) reduction in letter chart scores - was reduced by as much as 47% among people taking natalizumab, compared to those taking placebo.
"Not only do the findings of the study add to our understanding of the effects of natalizumab, but the results provide strong validation for a simple, sensitive, cost-effective, and clinically meaningful measure of visual function in MS," advises Dr. Nicholas LaRocca, Associate Vice President, Health Care Delivery and Policy Research at the National MS Society.
The researchers caution that, as with any therapy, the benefits of natalizumab must be considered in the context of potential risks or complications. In the case of natalizumab, three confirmed cases of progressive multifocal leukoencephalopathy (PML) - a rare, often lethal brain disease - have been reported.
Despite the fact that vision loss is a common and important cause of disability in MS, the natalizumab clinical trials were the first to include a test of visual function. These trials showed that low-contrast letter acuity eye chart testing is an effective measure for assessing visual outcomes, and may be useful in future clinical trials.
University of Pennsylvania School of Medicine
Vision Loss Current Events and Vision Loss News RSSCase Western Reserve University research finds drug candidate slows age-related macular degeneration
Research results from the Case Western Reserve University School of Medicine show that the progression of age-related macular degeneration (AMD) is markedly slowed in new laboratory-engineered mice when they received treatments of retinylamine, a trial drug that has been tested in a medical school lab.
Receptor could halt blinding diseases, stop tumor growth, preserve neurons after trauma
An international team of researchers has discovered what promises to be the on-off switch behind several major diseases.
Safety study indicates gene therapy for blindness improves vision
All three people who received gene therapy at the University of Florida to treat a rare, incurable form of blindness have regained some of their vision, according to a paper published online today in Human Gene Therapy.
Virus weaves itself into the DNA transferred from parents to babies
Parents expect to pass on their eye or hair color, their knobby knees or their big feet to their children through their genes. But they don't expect to pass on viruses through those same genes.
Scientists unmask brain's hidden potential
Previous research has found that when vision is lost, a person's senses of touch and hearing become enhanced. But exactly how this happens has been unclear.
Eat oily fish at least once a week to protect your eyesight in old age
Eating oily fish once a week may reduce age-related macular degeneration (AMD) which is the major cause of blindness and poor vision in adults in western countries and the third cause of global blindness, according to a study published today in the American Journal of Clinical Nutrition.
Corneal transplant technique shows promise in children
For infants and children with blinding diseases of the cornea, a sophisticated new corneal transplantation technique offers the hope of improving vision while overcoming the technical difficulty and low success rate of traditional penetrating keratoplasty (PK) in children, according to reports in the current issue of the Journal of AAPOS (American Association for Pediatric Ophthalmology and Strabismus).
Retina transplants show promise in patients with retinal degeneration
Preliminary research shows encouraging results with transplantation of retinal cells in patients with blindness caused by retinitis pigmentosa (RP) and age-related macular degeneration (AMD).
Gene therapy involving antibiotics may help patients with Usher syndrome
A new approach to treating vision loss caused by Type 1 Usher syndrome (USH1), the most common condition affecting both sight and hearing, will be unveiled by a scientist at the annual conference of the European Society of Human Genetics.
Study shows pine bark naturally reduces cardiovascular risk factors in diabetics
A new study published in the May 2008 (volume 8, issue 25) edition of the journal of Nutrition Research shows Pycnogenol (pic-noj-en-all), an antioxidant plant extract from the bark of the French maritime pine tree, reduces blood sugar in type II diabetes patients, allows people to lower their antihypertensive medication and improves cardiovascular disease (CVD) risk factors.
More Vision Loss Current Events and Vision Loss News Articles
 | Dealing With Vision Loss by Fred Olver Dealing With Vision Loss offers information all in one place For people who are experiencing vision loss, For family members whose parent, friend or sibling is experiencing vision loss and Information for parents of children who were born with a significant vision loss Dealing With Vision Loss will help family members understand how the person who is losing their sight is feeling and... |
 | Coping with Vision Loss: Maximizing What You Can See and Do by Bill Chapman This book begins with a promise: people with severe vision loss can be trained and equipped to function as sighted. The author, himself legally blind for 30 years, fulfills that promise with precise information and guidance on improving life through visual rehabilitation. The book explains fundamental facts about eyes and vision, including the causes and varieties of blindness, and then moves on... |
| Making Life More Livable : Simple Adaptations for Living at Home After Vision Loss by Maureen A. Duffy, Irving R. Dickman | |
 | Macular Disease: Practical Strategies for Living with Vision Loss by Peggy R. Wolfe This invaluable guide to living well with vision loss is the perfect blend of abundant factual material and real-life experience. The book's positive, take-charge approach offers reassurance, hope, and hundreds of proven techniques, strategies, and tips for both the newly diagnosed and those at later stages of their disease. "My Story" vignettes in each chapter describe the author's fears,... |
 | Love Yourself Thin: The Revolutionary Spiritual Approach to Weight Loss (Visions, Signet) by Victoria Moran Finally, you can have a body that you know is gorgeous. Victoria Moran has discovered the ultimate way to control weight and develop consistent positive self-esteem with her "Love-Based Diet"--based on the principles of a 12-step program. This program reveals how physical, emotional, and spiritual aspects of your life can be employed to help you stop being a problem, binge, or compulsive eater.... |
 | Aging and Vision Loss: A Handbook for Families by Alberta L. Orr |
 | Small Victories: Conversations About Prematurity, Disability, Vision Loss, and Success by Mary Lou Pierce-Dickerson Each year, approximately 400,000 babies are born prematurely in the United States. Little information exists to help parents deal with the challenges of having an infant with many medical needs and the resulting stresses they encounter. Small Victories offers a selection of interviews with indiviuals who were born prematurely and with parents of children who were born prematurely who ... |
| Meeting the Needs of People With Vision Loss: A Multidisciplinary Perspective | |
 | Lighthouse International Guide to Low Vision Defined: A Guide to the Major Causes of Vision Loss and What Can Be Done to Improve Functional Vision by Eleanor E Faye MD, Karen Seidman MPA, William Stappenbeck |
 | Vision Loss in an Aging Society: A Multidisciplinary Perspective Vision Loss in an Aging Society is a thoughtful and challenging overview that integrates practice and policy issues relating to aging and visual impairment and reflects the perspectives of leading experts in the fields of vision rehabilitation and aging. This essential reference outlines the critical components of public policy changes urgently needed in view of demographic trends and is an... |
| © 2008 BrightSurf.com |